Literature DB >> 6432999

Production and antagonism of cutaneous vascular permeability in the guinea pig in response to histamine, leukotrienes and A23187.

L E Rinkema, K G Bemis, J H Fleisch.   

Abstract

The method of Katayama et al. (Microbiol. Immunol. 22:89-101, 1978) for assessing cutaneous vascular permeability was modified and used to evaluate responses of the dermal vasculature to histamine, leukotriene (LT)C4, LTD4 and the ionophore A23187. These agonists were given intradermally, whereas antagonists and other types of inhibitors were administered i.v. Histamine was shown to cause vascular leakage via an H1 receptor. No evidence for H2 receptor activation or involvement of cyclooxygenase products was found. The results also suggested that a portion of the response to histamine was due to the liberation of LTD4. LTC4 produced a mixed response comprised of vasoconstriction and increased vascular permeability, the latter possibly due to its conversion to LTD4. FPL 55712 antagonized LTD4-induced permeability in a dose-dependent manner, whereas indomethacin had no effect. Neither pyrilamine nor FPL 55712 reduced the response to A23187. A dose of indomethacin that did not affect the response to A23187 when given alone markedly reduced the ability of ionophore to cause vascular leakage when combined with either pyrilamine or FPL 55712. Thus, histamine and LTD4, in combination with one or more of the cyclooxygenase products, may be involved in A23187-induced cutaneous vascular permeability. Finally, two calcium channel blocking agents, nifedipine and diltiazem, did not block the vascular leakage caused by A23187.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6432999

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma.

Authors:  Y Nakamura; M Hoshino; J J Sim; K Ishii; K Hosaka; T Sakamoto
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

Review 2.  Leukotriene activity modulation in asthma.

Authors:  S L Spector
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

3.  Effect of prostaglandin E1 on leukotriene C4-induced increases in vascular permeability of hamster cheek pouch.

Authors:  T Yong; W G Mayhan
Journal:  Inflammation       Date:  1992-04       Impact factor: 4.092

Review 4.  Leukotriene-receptor antagonists. Role in asthma management.

Authors:  A D D'Urzo; K R Chapman
Journal:  Can Fam Physician       Date:  2000-04       Impact factor: 3.275

5.  Pulmonary and systemic host response to Streptococcus pneumoniae and Klebsiella pneumoniae bacteremia in normal and immunosuppressed mice.

Authors:  E Wang; N Ouellet; M Simard; I Fillion; Y Bergeron; D Beauchamp; M G Bergeron
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

6.  Evaluation of LY163443, 1-[2-hydroxy-3-propyl-4-([4- (1H-tetrazol-5-ylmethyl)phenoxy]methyl) phenyl]ethanone, as a pharmacologic antagonist of leukotrienes D4 and E4.

Authors:  J H Fleisch; L E Rinkema; K D Haisch; D McCullough; F P Carr; R D Dillard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-05       Impact factor: 3.000

Review 7.  Management of asthma with zafirlukast. Clinical experience and tolerability profile.

Authors:  S L Spector
Journal:  Drugs       Date:  1996       Impact factor: 9.546

8.  Pulmonary aerosol actions of LY188695 (KB2413), a new potent H1-receptor antagonist.

Authors:  S A Silbaugh; P W Stengel; L E Rinkema
Journal:  Agents Actions       Date:  1987-06

9.  5-lipoxygenase knockout mice exhibit a resistance to acute pancreatitis induced by cerulein.

Authors:  Salvatore Cuzzocrea; Antonietta Rossi; Ivana Serraino; Rosanna Di Paola; Laura Dugo; Tiziana Genovese; Domenico Britti; Giuseppe Sciarra; Angelina De Sarro; Achille P Caputi; Lidia Sautebin
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

10.  Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans.

Authors:  Samir M Parikh; Tadanori Mammoto; Aylit Schultz; Hai-Tao Yuan; David Christiani; S Ananth Karumanchi; Vikas P Sukhatme
Journal:  PLoS Med       Date:  2006-03       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.